Concizumab as a Subcutaneous Prophylactic Treatment Option for Patients with Hemophilia A or B: A Review of the Evidence and Patient’s Perspectives

References

• Petersen LC. The hemostatic properties of TFPI antibody. Thromb Res. 2012;129(Suppl 2):S44–5S4. doi:10.1016/j.thromres.2012.02.030
   PubMed Web of Science ®Google Scholar
• Butterfield JSS, Hege KM, Herzog RW, Kaczmarek R, Molecular A. Revolution in the treatment of hemophilia. Mol Ther. 2020;28(4):997–1015. doi:10.1016/j.ymthe.2019.11.006
   PubMed Web of Science ®Google Scholar
• Roberts HR, Monroe DM, Oliver JA, et al. Newer concepts of blood coagulation. Haemophilia. 1998;4(4):331–334. doi:10.1046/j.1365-2516.1998.440331.x
   PubMed Web of Science ®Google Scholar
• Broze GJ, Girard TJ. Tissue factor pathway inhibitor: structure-function. Front Biosci. 2012;17(1):262–280. doi:10.2741/3926
   Web of Science ®Google Scholar
• Wood JP, Ellery PER, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood. 2014;123(19):2934–2943. doi:10.1182/blood-2013-11-512764
   PubMed Web of Science ®Google Scholar
• Wun TC, Kretzmer KK, Girard TJ, et al. Cloning and characterization of a cDNA coding for the lipoprotein-associated coagulation inhibitor shows that it consists of three tandem kunitz-type inhibitory domains. J Biol Chem. 1988;263(13):6001–6004. doi:10.1016/S0021-9258(18)68737-X
   PubMed Web of Science ®Google Scholar
• Chowdary P. Anti-tissue factor pathway inhibitor (TFPI) therapy: a novel approach to the treatment of hemophilia. Int J Hematol. 2020;111(1):42–50. doi:10.1007/s12185-018-2548-6
   PubMed Web of Science ®Google Scholar
• Sidonio RF, Zimowski KL. TFPI blockade: removing coagulation’s brakes. Blood. 2019;134(22):1885–1887. doi:10.1182/blood.2019002900
   PubMed Web of Science ®Google Scholar
• Mahlangu JN. Progress in the development of anti-tissue factor pathway inhibitors for hemophilia management. Front Med. 2021;8:670526. doi:10.3389/fmed.2021.670526
   PubMed Web of Science ®Google Scholar
• Hilden I, Lauritzen B, Søerensen BB, et al. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood. 2012;119(24):5871–5878. doi:10.1182/blood-2012-01-401620
   PubMed Web of Science ®Google Scholar
• Agersø H, Overgaard RV, Petersen MB, et al. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. Eur J Pharm Sci. 2014;56:65–69. doi:10.1016/j.ejps.2014.02.009
   PubMed Web of Science ®Google Scholar
• Hansen L, Petersen LC, Lauritzen B, et al. Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz–type protease inhibitor 2 domain of tissue factor pathway inhibitor. Thromb Res. 2014;133(3):464–471. doi:10.1016/j.thromres.2013.12.015
   PubMed Web of Science ®Google Scholar
• Lauritzen B, Hilden I. Concizumab promotes haemostasis via a tissue factor‐factor VIIa–dependent mechanism supporting prophylactic treatment of hemophilia: results from a rabbit hemophilia bleeding model. Hemophilia. 2019;25(6):e379–e382. doi:10.1111/hae.13861
   PubMed Web of Science ®Google Scholar
• Lauritzen B, Olling J, Abel KL, et al. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits. J Thromb Haemost. 2019;17(3):460–469. doi:10.1111/jth.14380
   PubMed Web of Science ®Google Scholar
• Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13(5):743–754. doi:10.1111/jth.12864
   PubMed Web of Science ®Google Scholar
• Chowdary P. Inhibition of tissue factor pathway inhibitor (TFPI) as a treatment for hemophilia: rationale with focus on concizumab. Drugs. 2018;78(9):881–890. doi:10.1007/s40265-018-0922-6
   PubMed Web of Science ®Google Scholar
• Waters EK, Sigh J, Friedrich U, et al. Concizumab, an anti-tissue factor pathway inhibitor antibody, induces increased thrombin generation in plasma from hemophilia patients and healthy subjects measured by the thrombin generation assay. Hemophilia. 2017;23(5):769–776. doi:10.1111/hae.13260
   PubMed Web of Science ®Google Scholar
• Eichler H, Angchaisuksiri P, Kavakli K, et al. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. J Thromb Haemost. 2018;16(11):2184–2195. doi:10.1111/jth.14272
   PubMed Web of Science ®Google Scholar
• Shapiro AD, Angchaisuksiri P, Astenmark J, et al. Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results. Blood. 2019;134(22):1973–1982. doi:10.1182/blood.2019001542
   PubMed Web of Science ®Google Scholar
• Shapiro AD. Concizumab: a novel anti-TFPI therapeutic for hemophilia. Blood Adv. 2021;5(1):279. doi:10.1182/bloodadvances.2019001140
   PubMed Web of Science ®Google Scholar
• Yuan D, Rode F, Cao Y. A systems pharmacokinetic/pharmacodynamic model for concizumab to explore the potential of anti-TFPI recycling antibodies. Eur J Pharm Sci. 2019;1(138):105032. doi:10.1016/j.ejps.2019.105032
   Web of Science ®Google Scholar
• Kjalke M, Kjelgaard-Hansen M, Andersen S, Hilden I. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: in vitro and ex vivo analyses. J Thromb Haemost. 2021;19(7):1687–1696. doi:10.1111/jth.15323
   PubMed Web of Science ®Google Scholar
• Kasper CK, Graham J. Pool and the discovery of cryoprecipitate. Haemophilia. 2012;18(6):833–835. doi:10.1111/hae.12042
   PubMed Web of Science ®Google Scholar
• von Mackensen S, Kalnins W, Krucker J, et al. Hemophilia patients’ unmet needs and their expectations of the new extended half-life factor concentrates. Hemophilia. 2017;23(4):566–574. doi:10.1111/hae.13221
   PubMed Web of Science ®Google Scholar
• Parnes A, Mahalangu JN, Pipe SW, et al. Patient preference for emicizumab versus prior factor therapy in people with hemophilia A: results from the HAVEN 3 and HAVEN 4 studies. Hemophilia. 2021;27(6):e772–e775. doi:10.1111/hae.14421
   PubMed Web of Science ®Google Scholar
• Young G, Liesner R, Chang T, et al. A multicenter, open label, phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood. 2019;134(24):2127–2138. doi:10.1182/blood.2019001869
   PubMed Web of Science ®Google Scholar
• Pipe S, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with hemophilia A (HAVEN4): a multicenter, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6(6):e295–e305. doi:10.1016/S2352-3026(19)30054-7
   PubMed Web of Science ®Google Scholar
• Kaczmarek R, Herzog RW. Treatment-induced hemophilic thrombosis? Mol Ther. 2022;30(2):505–506. doi:10.1016/j.ymthe.2022.01.015
   PubMed Web of Science ®Google Scholar
• Hoffman M. Thrombosis and novel hemophilia therapies: the fine line between clotting and bleeding. Blood Adv. 2021;5(18):3736. doi:10.1182/bloodadvances.2021004802C
   PubMed Web of Science ®Google Scholar
• Chowdary P, Eichler H, Matsushita T, et al. Dose optimisation and risk mitigation during concizumab prophylaxis in patients with haemophilia A/B with and without inhibitors in phase 3 clinical trials. Haemophilia. 2022;28:27–27
   PubMed Web of Science ®Google Scholar
• Astermark J, Angchaisuksiri P, Kavakli K, et al. Management of breakthrough bleeds during concizumab prophylaxis in patients with haemophilia A/B with and without inhibitors in phase 3 clinical trials. Haemophilia. 2022;28(S1):70–1 (PO087).
   Google Scholar
• Pierce GF, Hart DP, Kaczmarek R. Committee on Coagulation Products Safety Supply, Access (CPSSA) of the World Federation of Hemophilia (WFH). Safety and efficacy of emicizumab and other novel agents in newborns and infants. Haemophilia. 2019;25(5):e334–e335. doi:10.1111/hae.13822
   PubMed Web of Science ®Google Scholar